Related Experiment Videos
Smooth muscle antibody in malignant disease
British Medical Journal
|November 27, 1971
Summary
Smooth muscle antibody (SMA) is more prevalent in patients with malignant diseases, particularly ovarian cancer and melanoma. This suggests SMA may indicate changes in cancer cell membranes.
Area of Science:
- Immunology
- Oncology
- Gastroenterology
Background:
- Smooth muscle antibody (SMA) is an autoantibody.
- Its association with malignant diseases requires further investigation.
Purpose of the Study:
- To determine the prevalence of SMA in patients with malignant diseases compared to controls.
- To explore the potential link between SMA and specific cancer types.
- To describe a novel antibody targeting bile canaliculi.
Main Methods:
- Sera from 80 patients with malignant disease and 46 controls were tested for SMA.
- Antibody titers were determined using immunofluorescence assays.
- Incidence was analyzed across different cancer types.
Main Results:
- SMA (≥1:10) was detected in 67.5% of malignant disease patients versus 20% of controls.
- Prevalence varied by cancer type, notably 60% in malignant melanoma and 83% in ovarian carcinoma.
- A new antibody targeting bile canaliculi was identified.
Conclusions:
- Elevated SMA levels are associated with malignant diseases.
- SMA presence may correlate with malignant cell membrane alterations.
- The newly described antibody warrants further characterization.